LCTX Lineage Cell Therapeutics Inc

USD 1.14 0.00 0
Icon

Lineage Cell Therapeutics Inc (LCTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.14

0.00 (0.00)%

USD 0.28B

0.33M

N/A

N/A

Icon

LCTX

Lineage Cell Therapeutics Inc (USD)
COMMON STOCK | NYE
USD 1.14
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.28B

N/A

USD 1.14

Lineage Cell Therapeutics Inc (LCTX) Stock Forecast

N/A

Based on the Lineage Cell Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Lineage Cell Therapeutics Inc is not available over the next 12 months. Lineage Cell Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lineage Cell Therapeutics Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Lineage Cell Therapeutics Inc’s stock price was USD 1.14. Lineage Cell Therapeutics Inc’s stock price has changed by -0.87% over the past week, -10.24% over the past month and -17.39% over the last year.

No recent analyst target price found for Lineage Cell Therapeutics Inc
No recent average analyst rating found for Lineage Cell Therapeutics Inc

Company Overview Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Ph...Read More

https://www.lineagecell.com

2173 Salk Avenue, Carlsbad, CA, United States, 92008

68

December

USD

USA

Adjusted Closing Price for Lineage Cell Therapeutics Inc (LCTX)

Loading...

Unadjusted Closing Price for Lineage Cell Therapeutics Inc (LCTX)

Loading...

Share Trading Volume for Lineage Cell Therapeutics Inc Shares

Loading...

Compare Performance of Lineage Cell Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for LCTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Lineage Cell Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S +3.38 (+2.70%) USD562.30B 46.44 4.90

ETFs Containing LCTX

Symbol Name LCTX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Lineage Cell Therapeutics Inc (LCTX) Stock

Stock Target Advisor's fundamental analysis for Lineage Cell Therapeutics Inc's stock is Slightly Bullish .

Unfortunately we do not have enough data on LCTX's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on LCTX's stock to indicate what its average analyst target is.

LCTX stock's Price/Earning ratio is 3.63. Our analysis grades LCTX stock's Price / Earning ratio at C-. This means that LCTX stock's Price/Earning ratio is above 29% of the stocks in the Biotechnology sector in the NYE exchange. Based on this LCTX may be undervalued for its sector.

The last closing price of LCTX's stock was USD 1.14.

The most recent market capitalization for LCTX is USD 0.28B.

Unfortunately we do not have enough analyst data on LCTX's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Lineage Cell Therapeutics Inc's stock.

As per our most recent records Lineage Cell Therapeutics Inc has 68 Employees.

Lineage Cell Therapeutics Inc's registered address is 2173 Salk Avenue, Carlsbad, CA, United States, 92008. You can get more information about it from Lineage Cell Therapeutics Inc's website at https://www.lineagecell.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...